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Abstract 
A simple mimetic of a heparan sulfate disaccharide sequence that binds to the growth 
factors FGF-1 and FGF-2 was synthesized by coupling a 2-azido-2-deoxy-D-glucosyl 
trichloroacetimidate donor with a 1,6-anhydro-2-azido-2-deoxy--D-glucose acceptor. 
Both the donor and acceptor were obtained from a common intermediate readily obtained 
from D-glucal. Molecular docking calculations showed that the predicted locations of the 
disaccharide sulfo groups in the binding site of FGF-1 and FGF-2 are similar to the 
positions observed for co-crystallized heparin-derived oligosaccharides obtained from 
published crystal structures.  
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The fibroblast growth factors FGF-1 and FGF-2 are proteins that play important 
roles in tumor angiogenesis.
1
 They initiate this process by binding with their receptors 
(FGFRs) and heparan sulfate (HS) to form a ternary complex which leads to receptor 
dimerization/activation and subsequent cell signalling.
2
 Inhibiting the formation of the 
HS:FGF:FGFR complex by antagonising HS-FGF binding with HS mimetics is thus a 
viable strategy for antiangiogenic therapies.
3-5
  
Various groups have reported the synthesis of HS and HS-like oligosaccharides 
designed to interact with FGF-1 or FGF-2.
6-8
 These studies have provided valuable 
information about the structural requirements for oligosaccharide-FGF binding and 
activation, however, the syntheses of such oligosaccharides are difficult and laborious. 
This has lead to the pursuit of less synthetically challenging oligosaccharide mimetics as 
FGF antagonists.
9-12
  As part of a program aimed at developing antiangiogenic 
compounds, we recently described
12
 the preparation of simple disaccharides such as 2 and 
3 which mimic the HS disaccharide GlcN(2S, 6S)-IdoA(2S) (1, Fig. 1) which has been 
postulated from X-ray crystallographic analyses as a minimal heparin/HS consensus 
sequence for FGF binding.
13
 As well as maintaining the -(14) linkage between the 
two monosaccharide units and the spatial orientation of the two key sulfo groups 
[GlcN(2S) and IdoA(2S)], the compounds were designed to mimic the conformational 
flexibility
14,15
 of the IdoA residue. Docking calculations showed that the predicted 
locations of disaccharide sulfo groups in the binding site of FGF-1 were consistent with 
the positions observed for co-crystallized heparin-derived oligosaccharides. Docking 
scores correlated with experimental Kd values (22 M to 1.4 mM) obtained from binding 
assays.
12
 The docking score for a model HS disaccharide binding to FGF-1 was similar.
12
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Figure 1. Structures of the GlcN(2S, 6S)-IdoA(2S) disaccharide sequence 1, which represents a 
minimal consensus sequence for FGF:HS binding,
13
 and two conformationally flexible mimetics 2 
and 3.
12
 
 
In crystal structures of heparin oligosaccharides bound to FGF, IdoA is found in 
the 
1
C4 conformation when bound only to the protein
16,17
 or in a skew-boat (
2
SO) 
conformation when part of a ternary complex.
18,19
 NMR studies also indicate that FGF-1 
can bind both conformations of IdoA in a bioactive hexasaccharide.
20
 These observations 
led us to consider the synthesis of simple disaccharides in which the IdoA mimic is 
locked in the 
1
C4 conformation. A similar approach has been successfully used to probe 
the active conformations of the ATIII-binding heparin pentasaccharide.
21,22
 
 
It has been demonstrated that an O-sulfo group can substitute for an N-sulfo group 
in a heparin oligosaccharide without loss of binding affinity.
23
 The known 1,6-anhydro-2-
azido-2-deoxy--D-glucopyranose 8 was thus identified as a suitable IdoA mimic 
precursor because it is locked in the required 
1
C4 conformation, can be selectively 
sulfonated at the C-2 position and is readily available in four steps from D-glucal (4) via 
 5  
intermediates 5-7.
24
  The precursor to 8 in this sequence of transformations can, in fact, 
be easily converted, via intermediates 9-11, into useful glycosyl donors such as the 
imidate 12 for use in the synthesis of heparin/HS oligosaccharides.
24-26
 It was therefore 
decided to prepare both 8 and 12 and use them to synthesize a disaccharide (17) with the 
desired features. 
 
Figure 2 
 
  
Following literature precedent,
27
 TBDMSOTf was selected as the promoter for the 
glycosylation of the alcohol 8 with the imidate 12.  The reaction proceeded well in 
dichloromethane at –20 C, however, a chromatographically inseparable mixture of 
anomers resulted (: = 3.8:1).  The product was thus converted into the tribenzoate via 
Zémplen deacetylation followed by benzoylation with benzoyl chloride and pyridine, and 
the desired -linked disaccharide 13 was isolated by flash chromatography in good 
overall yield (46%, 3 steps, Scheme 2), along with 12% of the -linked disaccharide 13b.  
The azide groups of 13 were then reduced via transfer hydrogenation with ammonium 
formate over Pd(OH)2 catalyst and the resulting diamine 14 was sulfonated with 
SO3·trimethylamine complex and debenzoylated (1M NaOH) to give the benzyl ether 16 
 6  
in moderate overall yield (28%, 3 steps).  Hydrogenolysis over Pd(OH)2 at 50 psi then 
furnished the target disaccharide 17 in excellent yield (98%).   
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O
N3
BzO
BzO
O
N3
O
OBn
O
OBz
8 + 12
a, b
13
O
H2N
BzO
BzO
O
H2N
O
OBn
O
OBz
14
O
HN
BzO
BzO
O
HN
O
OBn
O
OBz
SO3Na
SO3Na
O
HN
HO
HO
O
HN
O
OR
O
OH
SO3Na
SO3Na
15
16 R = Bn
17 R = H
c
d
e
f
 
a) TBDMSOTf, CH2Cl2, -20 C; b) i. NaOMe, MeOH, ii. BzCl, pyridine, 46%, 3 steps; c) Pd(OH)2, 
NH4HCO2, EtOAc/MeOH, 58%; d) SO3·Me3N, DMF, 60 C; e) 1 M NaOH, 28%, 3 steps; f) H2, 
Pd(OH)2, 98%. 
 
Molecular docking calculations were performed using the Glide program
28
 to 
examine the binding modes of 16 and 17 with FGF-1 and FGF-2.  Compound 16 was 
examined in order to probe the effects of an extra hydrophobic group on FGF binding as 
it has been shown that some heparin derivatives with lipophilic modifications can bind to 
FGF-1 with similar or greater affinity than unmodified heparin.
29,30
 The poses of 16 and 
17 with the best GlideScores for binding to FGF-1 and FGF-2 are shown in Figure 3. 
 7  
Also shown are the van der Waals surfaces of the central sulfo groups of cocrystallized, 
heparin-derived hexa- and tetrasaccharide ligands from the crystal structures (pdb 
accession codes 2AXM 
16
 for FGF-1 and 1BFB
17
 for FGF-2, respectively).  
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Figure 3. The best Glide poses for 16 (grey C atoms) and 17 (green C atoms) docked with FGF-1 
(represented by a blue -carbon backbone) and FGF-2 (represented by an orange -carbon 
backbone). Also shown are the van der Waals surfaces of the sulfo groups of the heparin 
fragments cocrystallized with each growth factor (red O atoms and yellow S atoms). (a) The best 
poses for 16 (Gscore = -9.2 kcal/mol) and 17 (Gscore = -7.5 kcal/mol) docked with FGF-1; (b) 
The best poses for 16 (Gscore = -7.2 kcal/mol) and 17 (Gscore = -6.1 kcal/mol) docked with FGF-
2. Hydrogen bonding interactions are depicted by the dotted yellow lines. 
 
The preferred mode of binding of 16 and 17 to FGF-1 in Figure 3a shows 
congruence between the ligand sulfo groups with those observed crystallographically. 
The FGF-2 binding mode of 16, shown in Figure 3b, also shows the same congruence, 
however, the preferred mode for 17, involves ionic hydrogen bonding interactions with 
the positively charged residues LYS130 and LYS120 of FGF-2. These residues are not 
involved in binding to the cocrystallized heparin tetrasaccharide fragment, although their 
proximity to the binding site region and their inherent flexibility suggests that their 
involvement in ligand binding is reasonable. In the absence of confirmatory experimental 
binding data these results are not definitive. However, they do suggest that 
conformationally locked residues and hydrophobic substituents
29,30
 should be further 
explored in HS mimetic design to target amino acid residues adjacent to the HS-binding 
site of FGF-1 and FGF-2.  
 
In conclusion, a simple conformationally locked HS mimetic disaccharide was 
efficiently synthesized via the coupling of a 2-azido-2-deoxy-D-glucosyl 
trichloroacetimidate donor with a 1,6-anhydro-2-azido-2-deoxy--D-glucose acceptor. 
Both the donor and acceptor were obtained from a common intermediate readily obtained 
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from D-glucal. Molecular docking calculations indicated that the predicted locations of 
the disaccharide sulfo groups in the binding site of FGF-1 and FGF-2 are similar to the 
positions observed for co-crystallized heparin-derived oligosaccharides. These results 
may aid in the design of potential inhibitors of FGF-mediated angiogenesis. 
 
1.  Experimental 
1.1. General methods 
General experimental details have been given previously.
31
  Capillary electrophoresis 
(CE) was performed in reverse polarity mode with inverse UV detection, using 10 mM 5-
sulfosalicylic acid (pH 3) as the background electrolyte as previously described.
32
   
 
1.2. 3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-glucopyranosyl trichloroacetimidate (12). 
(a) A mixture of D-glucal (1.95 g, 13.3 mmol), (Bu3Sn)2O (5.44 mL, 10.6 mmol) and 
molecular sieves (4.0 g of 3Å powder) in MeCN (50 mL) was heated under reflux (3 h).  
The mixture was cooled (rt) and I2 (4.06 g, 16.0 mmol) was introduced with continued 
stirring (1.5 h).  The mixture was filtered and the filtrate washed with hexane (3  100 
mL) prior to evaporation of the solvent affording, presumably, the iodide 5 as a pale 
yellow oil.  This was used directly in the next reaction without further purification or 
characterization. (b) A mixture of the crude iodide and NaN3 (2.59 g, 39.9 mmol) in a 
mixture of DMF (45 mL) and H2O (5 mL) was heated under reflux (o/n) and then 
evaporated and co-evaporated (toluene).  The residue was treated with pyridine (10 mL), 
Ac2O (5 mL) and DMAP (50 mg) and the combined mixture stirred (rt, o/n).  The 
mixture was then treated with ice-water (10 mL) and stirring continued (3 h) before being 
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subjected to workup (EtOAc) and flash chromatography (1040% EtOAc/hexane) to 
yield the diacetate 9 as a colourless oil (1.90 g),  used in the next reaction without further 
purification or characterization.  (c) Conc. H2SO4 (50 L) was added to a cooled (0 °C) 
solution of crude 9 (2.33 g, 8.53 mmol) and Ac2O (5.00 mL, 49.0 mmol) in AcOH 
(10 mL) and the combined mixture stirred (0 °C→rt, o/n).  NaOAc (500 mg) was added 
portionwise until pH>5.0 and then the mixture was treated with MeOH (3 mL).  The 
mixture was filtered and the solvent evaporated and co-evaporated (toluene) prior to 
workup (EtOAc) to yield a colourless oil (3.04 g).   This residue was co-evaporated 
(MeCN, 2  100 mL) and used in the next reaction without further purification or 
characterization.  (d) Hydrazine acetate (921 mg, 10.0 mmol) was added to a stirred 
solution of the crude mixture from (c) (8.53 mmol, max.) in DMF (20 mL) and the 
combined mixture heated (55 C, 15 min).  The mixture was poured onto saturated brine 
and extracted (EtOAc).  The organic layer was evaporated and subjected to rapid silica 
filtration (1040% EtOAc/hexane) to yield, presumably, the hemiacetal 11 as a 
colourless oil (1.89 g, 76%, 2 steps).  This residue was co-evaporated (MeCN, 2  
100 mL) and used in the next reaction without further purification or characterization.  (e) 
K2CO3 (1.30 g, 9.5 mmol) was added to a solution of the hemiacetal 11 (1.85 g, 
6.3 mmol) and trichloroacetonitrile (2.0 mL, 20 mmol) in 1,2-DCE (20 mL) and the 
combined mixture stirred (0 ºCrt, 1 h).  The mixture was filtered, the solvent 
evaporated and the residue subjected to flash chromatography (10-30% EtOAc/hexane) to 
yield an anomeric mixture ( 9:1) of the imidate 12 as a colourless oil (2.19g, 80%).  
This mixture was separable by more careful chromatography and gave 
1
H NMR data in 
good agreement with the literature.
33,34
 - imidate:  1H NMR (400 MHz, CDCl3)  2.02, 
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2.03, 2.08 (3 s, 3 H each; 3  Ac), 3.74 (dd, 1 H, J1,2 = 3.6, J2,3 = 10.5 Hz; H-2); 4.06 (dd, 
1 H, J5,6a = 2.1, J6a,6b = 12.4 Hz; H-6a), 4.18 (ddd, 1 H, J4,5 = 10.3, J5,6b = 4.3 Hz; H-5), 
4.21 (dd, 1 H, H-6b), 5.12 (dd, 1 H, J3,4 = 9.4 Hz; H-4), 5.48 (dd, 1 H, H-3), 6.46 (d, 1 H, 
H-1), 8.80 (s, 1 H; NH). - imidate:  partial 1H NMR (400 MHz, CDCl3)  5.68 (d, 1 H, 
J1,2 = 8.4 Hz; H-1). 
 
1.3. 1,6-Anhydro-2-azido-3-O-benzyl-2-deoxy--D-glucopyranose (8). The alcohol 8 
was prepared according to the literature procedure
24,35
 by selective debenzylation of the 
dibenzyl ether 7 with TiCl4. 
1
H NMR (400 MHz, CDCl3)  1.96 (br s, 1 H; OH), 3.48-
3.49 (m, 1 H; H-2), 3.56-3.58 (m, 1 H; H-3), 3.64-3.66 (m, 1 H; H-4), 3.75 (dd, 1 H, J5,6a 
= 5.9, J6a,6b = 7.3 Hz; H-6a), 4.17 (dd, 1 H, J5,6b = 1.1, H-6b), 4.50-4.52 (m, 1 H; H-5), 
4.58, 4.61 (AB, JA,B 11.9 Hz; CH2Ph), 5.42-5.43 (m, 1 H; H-1), 7.26-7.36 (m, 5 H; Ph). 
 
1.4. 2-Azido-3,4,6-tri-O-benzoyl-2-deoxy--D-glucopyranosyl-(14)-1,6-anhydro-2-
azido-3-O-benzyl-2-deoxy--D-glucopyranose (13).  (a) A solution of the imidate 12 
(201 mg, 453 mol) and alcohol 8 (84 mg, 302 mol) in 1,2-DCE (5 mL) was stirred in 
the presence of activated mol. sieves (300 mg of 3Å powder) under an atmosphere of 
argon (rt, 30 min).  The mixture was cooled (20 C) with continued stirring (10 min) 
and TBDMSOTf (21 L, 91 mol) was introduced drop-wise and stirring maintained 
(20 C, 10 min).  Et3N (100 L) was introduced and the mixture filtered and evaporated.  
The residue was subjected to workup (EtOAc) and flash chromatography (1040% 
EtOAc/hexane) to yield a fraction presumed to contain the disaccharide product as a pale 
yellow oil (130 mg).  This residue was co-evaporated (2  10 mL MeCN) and used in the 
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next reaction without further purification or characterization. (b) A sliver of sodium was 
added to a stirred solution of the crude product from (a) (0.302 mmol, max.) in 
MeOH:THF (2:1, 3 mL) at 0 ºC.  The solution was allowed to warm to rt and stirred (3 
h). The mixture was neutralized (Bio-Rad AG
®
-50W-X8 resin, H
+
 form), filtered and the 
resin washed with MeOH. The combined filtrate and washings were evaporated to yield 
the alcohol as a colourless oil (98 mg). This residue was co-evaporated (2 10 mL 
MeCN) and used in the next reaction without further purification or characterization. (c) 
The crude product (0.302 mmol, max.) was dissolved in CH2Cl2 (3 mL) and treated with 
benzoyl chloride (1.3 eq per hydroxyl) and pyridine (1 mL).  The mixture was stirred at rt 
overnight, washed with ice-chilled 0.5 M HCl and sat. NaHCO3.  The organic phase was 
dried (MgSO4), filtered and evaporated, and the residue purified by flash chromatography 
(1030% EtOAc/hexane) to give, firstly, the -linked disaccharide 13 as a colourless 
foam (101 mg, 46%, 3 steps).  
1
H NMR (400 MHz, CDCl3)  3.11 (s, 1 H; H-2
I
), 3.41 
(dd, 1 H, J1,2 3.7, J2,3 10.7 Hz; H-6
I
), 3.61 (s, 1 H; H-3
I
), 3.39 (s, 1 H; H-4
I
), 4.05 (d, 1 H, 
J6,6 7.3 Hz; H-6
I
), 4.41-4.49 (m, 2 H; H-6
II
), 4.55, 4.68 (AB quartet, JA,B 11.9 Hz; 
CH2Ph), 4.79 (ddd, 1 H, J4,5 10.3, J5,6 2.9, 5.9 Hz; H-5
II
), 4.91 (br d, 1 H, J5,6 5.5 Hz; H-
5
I
), 5.08 (d, 1 H, J1,2 3.6 Hz; H-1
II
), 5.51 (dd, 1 H, J3,4 9.5, J4,5 10.2 Hz, H-4
II
), 5.60 (s, 
1 H,; H-1
I
), 6.10 (dd, 1 H, J2,3 10.7, J3,4 9.3 Hz; H-3
II
), 7.29-7.55, 7.89-8.03 (2 m, 20 H; 
ArH);  
13
C NMR (100 MHz, CDCl3)  58.7, 61.5, 63.3, 64.8, 69.2, 69.5, 70.5, 73.2, 74.6, 
78.1, 79.6, 100.7, 101.2, 128.1, 128.4, 128.5(8), 128.6(1), 128.6(4), 128.8, 128.9, 129.2, 
129.8(6), 129.9(0), 130.1, 130.2, 133.4, 133.5, 133.7, 137.2, 165.6(1), 165.6(2), 166.3.  
Next, the -anomer 13b was obtained as a colourless oil (27 mg, 12%, 3 steps).  1H NMR 
(400 MHz, CDCl3)  3.19 (s, 1 H; H-2
I
), 3.74 (dd, 1 H, J5,6 6.2, J6,6 7.1 Hz; H-6
I
), 3.79-
 13  
3.88 (m, 2 H; H-2
II
, H-3
I
), 3.88 (ddd, J4,5 9.2, J5,6 3.1, 4.7 Hz; H-5
II
), 3.95 (br s, 1 H; H-
4
I
), 4.10 (d, 1 H, J6,6 7.3 Hz; H-6
I
), 4.34 (dd, 1 H; J5,6 4.9, J6,6 12.2 Hz; H-6
II
), 4.50 (dd, 
1 H, J5,6 3.1, J6,6 12.3 Hz, H-6
II
), 4.52, 4.59 (AB quartet, JA,B 12.0 Hz; CH2Ph), 4.65 (d, 
1 H, J1,2 7.9 Hz; H-1
II
), 4.69 (br d, 1 H, J5,6 5.5 Hz; H-5
I
), 5.44 (t, 1 H, J2,3=3,4 9.7 Hz; H-
3
II
), 5.49 (br s, 1 H; H-1
I
), 5.51 (t, 1 H, J3,4=4,5 9.6 Hz; H-4
II
), 7.23-7.50, 7.84-7.96 (2 m, 
20 H; ArH).  
 
1.5. 2-Deoxy-2-sulfamino-α-D-glucopyranosyl-(1→4)-1,6-anhydro-2-deoxy-2-
sulfamino-3-O-benzyl--D-glucopyranose, disodium salt (16).  The disaccharide 13 (95 
mg, 127 µmol), Pearlman’s catalyst (11 mg), and ammonium formate (300 mg) in 2:1 
MeOH:EtOAc (7 mL) was heated (65 ºC) under argon until complete by TLC (1 h).  The 
mixture was cooled to rt, filtered (0.2 m) and evaporated.  The crude product was 
purified by SPE (300 mg C18 Waters cartridge, equilibrated with 5:95 MeOH:H2O, 
gradient eluted 5:95  100:0 MeOH:H2O) to yield the diamine 14 (53 mg, 58%).  
Without further purification, to the diamine was added DMF (5 mL), SO3•Me3N (41 mg, 
295 µmol) and NaHCO3 (40 mg, 475 µmol).  The mixture was heated (60 C) for 1 h 
then cooled to rt and quenched with ice and Na2CO3 (sat. aq).  This suspension was stored 
at –18 C overnight and the sample was filtered and evaporated.  TLC indicated that 
partial hydrolysis of the benzoate groups had occurred (presumably in the workup 
procedure).  Water (1 mL) and NaOH (250 µL, 1 M) were added and the solution was 
stirred overnight then loaded directly onto a Bio-Gel P-2 (5  100 cm) column and 
purified by size exclusion chromatography (0.1 M ammonium bicarbonate, flow rate = 
2.8 mL/min). Fractions containing carbohydrate (determined by spotting onto silica gel 
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plates and visualization by charring) were checked for purity by CE and those deemed to 
be free of salt were pooled and lyophilized to give disulfate 16 (22 mg, 28 %, 3 steps) as 
an amorphous white solid.  
1
H NMR (400 MHz, D2O, solvent suppressed) δ 7.35-7.21 
(m, 5H, Ph), 5.43 (br s, 1H, H-1
I
), 5.18 (d, 1H, J1,2 = 3.6 Hz, H-1
II
), 4.72-4.69 (m, 1H, H-
5
I
), 4.54-4.52 (m, 2H, PhCH2), 4.05 (d, 1H, Jgem = 7.9 Hz, H-6a
I
), 3.85 (br s, 1H, H-3
I
), 
3.76-3.58 (m, 5H, H4
I
, H6b
I
, H5
II
, H6a
II
, 6b
II
), 3.51 (dd, 1H, J2-3 = 10.4, J3-4 = 9.1, H-3
II
), 
3.34 (dd, 1H, J3-4~4-5 = 9.2, H-4
II
), 3.23 (br s, 1H, H-2
I
), 3.12 (dd, 1H, H-2
II
);  
13
C NMR 
(100 MHz, CDCl3) δ: 133.3, 124.8, 124.6, 124.4, 96.9, 95.1, 72.7, 71.5, 70.8, 68.3, 68.2, 
67.2, 66.0, 61.0, 56.6, 54.0, 49.8. The purity was 99% by CE (tm = 14.9 min). 
 
1.6. 2-Deoxy-2-sulfamino-α-D-glucopyranosyl-(1→4)-1,6-anhydro-2-deoxy-2-
sulfamino--D-glucopyranoside, disodium salt (17).  A mixture of benzyl ether 16 
(12.9 mg, 20.8 µmol) and Pearlman’s catalyst (5 mg) in purified water (2 mL) was 
subjected to 50 psi H2 overnight.  The mixture was filtered and lyophilised to yield 10.7 
mg (98 %) of tetrol 17.  
1
H NMR (400 MHz, D2O) δ 5.47 (br s, 1H, H-1
I
), 5.20 (d, 1H, 
J1-2 = 3.5, H-1
II
), 4.68 (br d, 1H, J5-4 = 5.5, H-5), 4.07 (d, 1H, Jgem = 7.6, H-6A
I
), 3.98 (br 
s, 1H, H-3
I
), 3.75-3.64 (m, 4H), 3.52 (t, 1H, J2-3~3-4 = 9.3, H-3
II
), 3.34 (t, 1H, J3-4~4-5 = 9.3, 
H-4
II
), 3.13 (obs. dd [partially obscured by H2
I
], 1H, H-2
II
), 3.11 (br s, 1H, H-2
I
). Purity 
was 99% by CE (tm = 12.6 min).  
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